Matches in SemOpenAlex for { <https://semopenalex.org/work/W3462907> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W3462907 endingPage "7" @default.
- W3462907 startingPage "244" @default.
- W3462907 abstract "Metaiodobenzylguanidine (MIBG) is a guanethidine derivative that is selectively concentrated in sympathetic nervous tissue. MIBG labeled with 123I or 131I has proven to be a specific and sensitive tool for detection of primary and metastatic pheochromocytoma and neuroblastoma. Eleven patients, with refractory stage IV neuroblastoma were treated with a total of 23 courses of 131I-MIBG, 100-400 mCi/m2/course. Total activity administered per course ranged from 90-550 mCi; maximum cumulative radioactivity per patient was 1356 mCi. The 131I-MIBG was given as a 2 hour infusion. Total body dose was calculated from whole body activity measurements, ranging from 73-250 cGy. The main toxicity was thrombocytopenia, with platelet nadirs to less than 25,000/microL in 5/23 courses (5 patients), all occurring in patients with greater than 25% replacement by tumor in the bone marrow. Neutropenia to a nadir of less than 500/microL was seen in only 2 patients, both with greater than 50% bone marrow replacement after 2 and 4 courses of 131I-MIBG, respectively. Tumor doses were calculated in patients with an evaluable measurable lesion, and ranged from 312-6329 cGy per course. Two of the eleven patients had partial responses, with one long-term survivor with stage IV neuroblastoma with no evidence of active disease now 4 years off treatment. Two other patients survive with stable disease after 3 treatments, at 3+ and 5+ months. Seven patients died with progressive disease. This study shows that treatment with 131I-MIBG is safe and can be effective in refractory neuroblastoma, particularly in patients who do not have extensive bone and bone marrow involvement." @default.
- W3462907 created "2016-06-24" @default.
- W3462907 creator A5018441465 @default.
- W3462907 creator A5027320601 @default.
- W3462907 creator A5029742781 @default.
- W3462907 creator A5047806701 @default.
- W3462907 creator A5065413853 @default.
- W3462907 creator A5067717961 @default.
- W3462907 creator A5082049030 @default.
- W3462907 creator A5086986564 @default.
- W3462907 date "1991-10-01" @default.
- W3462907 modified "2023-10-16" @default.
- W3462907 title "Efficacy and safety of [131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma." @default.
- W3462907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1823827" @default.
- W3462907 hasPublicationYear "1991" @default.
- W3462907 type Work @default.
- W3462907 sameAs 3462907 @default.
- W3462907 citedByCount "21" @default.
- W3462907 countsByYear W34629072015 @default.
- W3462907 countsByYear W34629072018 @default.
- W3462907 countsByYear W34629072019 @default.
- W3462907 countsByYear W34629072022 @default.
- W3462907 crossrefType "journal-article" @default.
- W3462907 hasAuthorship W3462907A5018441465 @default.
- W3462907 hasAuthorship W3462907A5027320601 @default.
- W3462907 hasAuthorship W3462907A5029742781 @default.
- W3462907 hasAuthorship W3462907A5047806701 @default.
- W3462907 hasAuthorship W3462907A5065413853 @default.
- W3462907 hasAuthorship W3462907A5067717961 @default.
- W3462907 hasAuthorship W3462907A5082049030 @default.
- W3462907 hasAuthorship W3462907A5086986564 @default.
- W3462907 hasConcept C121332964 @default.
- W3462907 hasConcept C126322002 @default.
- W3462907 hasConcept C126894567 @default.
- W3462907 hasConcept C141071460 @default.
- W3462907 hasConcept C142424586 @default.
- W3462907 hasConcept C146357865 @default.
- W3462907 hasConcept C151730666 @default.
- W3462907 hasConcept C2776715637 @default.
- W3462907 hasConcept C2777063308 @default.
- W3462907 hasConcept C2780007613 @default.
- W3462907 hasConcept C29730261 @default.
- W3462907 hasConcept C2989005 @default.
- W3462907 hasConcept C54355233 @default.
- W3462907 hasConcept C71924100 @default.
- W3462907 hasConcept C81885089 @default.
- W3462907 hasConcept C86803240 @default.
- W3462907 hasConcept C87355193 @default.
- W3462907 hasConcept C90924648 @default.
- W3462907 hasConceptScore W3462907C121332964 @default.
- W3462907 hasConceptScore W3462907C126322002 @default.
- W3462907 hasConceptScore W3462907C126894567 @default.
- W3462907 hasConceptScore W3462907C141071460 @default.
- W3462907 hasConceptScore W3462907C142424586 @default.
- W3462907 hasConceptScore W3462907C146357865 @default.
- W3462907 hasConceptScore W3462907C151730666 @default.
- W3462907 hasConceptScore W3462907C2776715637 @default.
- W3462907 hasConceptScore W3462907C2777063308 @default.
- W3462907 hasConceptScore W3462907C2780007613 @default.
- W3462907 hasConceptScore W3462907C29730261 @default.
- W3462907 hasConceptScore W3462907C2989005 @default.
- W3462907 hasConceptScore W3462907C54355233 @default.
- W3462907 hasConceptScore W3462907C71924100 @default.
- W3462907 hasConceptScore W3462907C81885089 @default.
- W3462907 hasConceptScore W3462907C86803240 @default.
- W3462907 hasConceptScore W3462907C87355193 @default.
- W3462907 hasConceptScore W3462907C90924648 @default.
- W3462907 hasIssue "4" @default.
- W3462907 hasLocation W34629071 @default.
- W3462907 hasOpenAccess W3462907 @default.
- W3462907 hasPrimaryLocation W34629071 @default.
- W3462907 hasRelatedWork W1490390872 @default.
- W3462907 hasRelatedWork W1983649081 @default.
- W3462907 hasRelatedWork W2029658174 @default.
- W3462907 hasRelatedWork W2054329419 @default.
- W3462907 hasRelatedWork W2144463537 @default.
- W3462907 hasRelatedWork W2351796763 @default.
- W3462907 hasRelatedWork W2439875401 @default.
- W3462907 hasRelatedWork W2522805621 @default.
- W3462907 hasRelatedWork W2569838665 @default.
- W3462907 hasRelatedWork W3462907 @default.
- W3462907 hasVolume "35" @default.
- W3462907 isParatext "false" @default.
- W3462907 isRetracted "false" @default.
- W3462907 magId "3462907" @default.
- W3462907 workType "article" @default.